Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.98, but opened at $6.51. Aura Biosciences shares last traded at $6.9450, with a volume of 49,293 shares changing hands.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the stock. Citigroup reissued a “market outperform” rating on shares of Aura Biosciences in a research report on Tuesday, November 10th. HC Wainwright decreased their price target on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Finally, Wall Street Zen raised Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aura Biosciences has an average rating of “Moderate Buy” and an average price target of $17.50.
Read Our Latest Stock Report on Aura Biosciences
Aura Biosciences Trading Down 2.1%
The firm has a 50 day simple moving average of $6.53 and a 200 day simple moving average of $6.80. The firm has a market capitalization of $711.32 million, a PE ratio of -4.17 and a beta of 0.41.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. Research analysts forecast that Aura Biosciences, Inc. will post -1.48 earnings per share for the current year.
Hedge Funds Weigh In On Aura Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of AURA. Frazier Life Sciences Management L.P. lifted its holdings in Aura Biosciences by 39.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 7,100,000 shares of the company’s stock worth $50,410,000 after buying an additional 2,000,000 shares in the last quarter. Montanova Capital LLC grew its position in Aura Biosciences by 64.8% in the second quarter. Montanova Capital LLC now owns 7,206,217 shares of the company’s stock valued at $51,164,000 after acquiring an additional 2,833,333 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Aura Biosciences during the second quarter valued at approximately $924,000. Nantahala Capital Management LLC acquired a new position in Aura Biosciences during the 2nd quarter valued at about $20,952,313. Finally, Jupiter Topco LLC acquired a new stake in Aura Biosciences in the 2nd quarter valued at about $17,788,000. 96.75% of the stock is owned by hedge funds and other institutional investors.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.
Read More
- Five stocks we like better than Aura Biosciences
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
